Culture and Expansion of Tumor-Infiltrating Lymphocyte From Biopsy Tissue Samples of Gastric Cancer Are Feasible [0.03%]
Bitna Park,Hanna Park,Min-Jung Seo et al.
Bitna Park et al.
Adoptive transfer of tumor-infiltrating lymphocytes (TILs) achieves promising clinical results in solid tumors. TIL trials use surgically resected tissue to isolate TILs. However, certain tissues are difficult to surgically resect, and a mi...
Brief Communication: Personalized Circulating Tumor DNA as a Predictor of Pathologic Response in Neoadjuvant Treatment of Resectable Melanoma [0.03%]
短篇通讯：循环肿瘤DNA作为可切除黑色素瘤新辅助治疗病理反应预测标志物的个性化模型
Justine V Cohen,Mofei Liu,Grace Rogers et al.
Justine V Cohen et al.
Patients with resectable stage III-IV melanoma are at high risk of recurrence following surgical excision. Neoadjuvant therapy (NEO) with immune checkpoint inhibition (ICI) improves event-free survival and may allow for pathologic treatment...
Side Effect Management of Immune-related Hepatotoxicity Due to Immune Checkpoint Inhibitors: A Multicenter Study by the Turkish Oncology Group (TOG) [0.03%]
土耳其肿瘤医学会多中心免疫检查点抑制剂相关自身免疫性肝毒性的管理研究
Ozden Demir,Bulent Cetin,Ali Alkan et al.
Ozden Demir et al.
The mechanism by which immune checkpoint inhibitors (ICI) cause immune-mediated liver injury is unclear. In 2017, the Society for Immunotherapy of Cancer (SITC) published guidelines for managing immunotherapy toxicity. This article aims to ...
Immunotherapy-Associated Autoimmune Hemolytic Anemia: Two Case Reports and a Literature Review [0.03%]
免疫治疗相关自身免疫性溶血性贫血：2例报告及文献复习
Mariana C Gouveia,Yumi R Shinkado,Ana Z L Pereira et al.
Mariana C Gouveia et al.
The advent of immune checkpoint inhibitors (ICIs) has transformed the treatment landscape of various malignancies. While these therapies have demonstrated significant efficacy, they are often accompanied by immune-related adverse events (ir...
Immune-Related Adverse Events Among Patients With Endometrial Cancer Receiving Pembrolizumab Alone or With Other Treatments: A Single-Center Real-World Experience [0.03%]
帕博利珠单抗单独或联合其他疗法治疗子宫内膜癌患者的免疫相关不良事件：单一中心的真实世界经验
Glenn Boyles,Chelsey Vranes,Nikita Sinha et al.
Glenn Boyles et al.
Immunotherapy has revolutionized endometrial cancer (EC) treatment; our objectives were to characterize immune-related adverse events (irAE) among EC patients and to identify factors associated with risk for irAE. Patients who received pemb...
Erratum: NUSAP1 Promotes Immunity and Apoptosis by the SHCBP1/JAK2/STAT3 Phosphorylation Pathway to Induce Dendritic Cell Generation in Hepatocellular Carcinoma [0.03%]
Erratum: NUSAP1通过SHCBP1/JAK2/STAT3磷酸化途径促进免疫和凋亡以诱导肝细胞癌中的树突状细胞生成
Guojie Chen,WenYa Li,Ruomu Ge et al.
Guojie Chen et al.
Sugemalimab for Post-PD-1 Progression in Non-small Cell Lung Cancer [0.03%]
度伐利尤单抗后进展的非小细胞肺癌患者的舒格利单抗治疗
Li Xu,Xingxiang Pu,Qianzhi Wang et al.
Li Xu et al.
This single-center, retrospective real-world study investigated the effectiveness and safety of sugemalimab-based rechallenge in patients with advanced non-small cell lung cancer who experienced disease progression after prior programmed ce...
Life-Threatening Radiation Necrosis After Complete Response to Pembrolizumab in a Patient With a Metastatic Silent PIT1 Pituitary Neuroendocrine Tumor (PitNET) [0.03%]
帕博利珠单抗治疗转移性无功能性PIT1垂体神经内分泌肿瘤(PitNET)获得完全缓解后出现威胁生命的放射性坏死症病例报告
Dario De Alcubierre,Tiziana Feola,Francesca Gianno et al.
Dario De Alcubierre et al.
Metastatic pituitary neuroendocrine tumors (metPitNETs) are rare neoplasms with limited therapeutic options. Temozolomide is the first-line therapy, but primary or secondary resistance frequently occurs. Immune checkpoint inhibitors (ICIs) ...
Erratum: BCMA-targeting Bispecific Antibody That Simultaneously Stimulates NKG2D-enhanced Efficacy Against Multiple Myeloma [0.03%]
Correction: 靶向BCMA的双特异性抗体同时刺激NKG2D，增强对多发性骨髓瘤的效果
Yang Wang,Hui Li,Wei Xu et al.
Yang Wang et al.
Survival Benefit of Immunotherapy in Patients With Stage IV Microsatellite Stable Rectal Cancer: A Propensity-Score Matched Analysis [0.03%]
微卫星稳定IV期直肠癌患者免疫治疗生存优势的倾向性匹配分析
Sameh Hany Emile,Nir Horesh,Zoe Garoufalia et al.
Sameh Hany Emile et al.
This study aimed to assess factors associated with overall survival (OS) in patients with microsatellite stable (MSS) stage IV rectal cancer treated with immunotherapy. In this retrospective review of the NCDB (2015-2021), patients with MSS...